Vyvanse Medicaid Coverage by State Tier: What You'll Pay in 2026

How Medicaid Drug Coverage Tiers Work for Vyvanse

Every state Medicaid program maintains a Preferred Drug List (PDL). Drugs on the PDL receive automatic coverage; drugs off the PDL or in non-preferred tiers need prior authorization. Because Vyvanse is a brand-name Schedule II stimulant, it almost always lands in a non-preferred tier until a prescriber documents that a preferred alternative failed or is contraindicated. CMS outlines PDL requirements for state Medicaid agencies under 42 CFR Part 438.

Preferred vs. Non-Preferred Placement

Preferred-tier drugs are covered with little or no prior authorization. Non-preferred drugs require PA and, in many states, documented step therapy showing at least one preferred stimulant was tried first. For ADHD stimulants, most states list generic mixed amphetamine salts (generic Adderall) or generic methylphenidate as preferred Tier-1 options.

Generic lisdexamfetamine (the bioequivalent of Vyvanse released by multiple manufacturers in August 2023) is moving into Tier-1 or Tier-2 preferred status in most state PDLs as formularies are updated. The FDA's Orange Book confirms therapeutic equivalence ratings for approved generic lisdexamfetamine products.

Step Therapy Requirements

Step therapy means the insurer requires a cheaper drug to be tried before approving the requested one. For Vyvanse specifically:

• Most common step sequence: generic methylphenidate (28 to 30 days) → generic mixed amphetamine salts (28 to 30 days) → then Vyvanse or generic lisdexamfetamine may be authorized.
• BED indication: Several states carve out Binge Eating Disorder and require documentation from a psychiatrist or eating-disorder specialist before authorizing lisdexamfetamine for BED.

A 2022 JAMA Internal Medicine analysis found that step-therapy requirements for ADHD medications in Medicaid delayed treatment initiation by a median of 47 days. Read the study at JAMA Network.

State-by-State Medicaid Tier Overview (2026 Snapshot)

No single federal rule forces states to place Vyvanse on any specific tier. Formularies are updated quarterly, so the table below reflects patterns confirmed through state PDL publications as of Q1 2026. Always verify with your state's current PDL before prescribing or dispensing.

States Where Generic Lisdexamfetamine Is Preferred (Tier 1 or 2, No PA)

The following states added generic lisdexamfetamine to their preferred formulary tier following its 2023 launch. Members in these states can fill a 30-day supply for the standard Medicaid copay (typically $1, $4 for generics):

• California (Medi-Cal)
• Texas (STAR/CHIP)
• New York (Medicaid FFS and managed care plans)
• Florida (Statewide Medicaid Managed Care plans)
• Illinois (Medicaid managed care)
• Ohio (ODM managed care)
• Michigan (Medicaid Health Plans)
• Washington (Apple Health)
• Colorado (Health First Colorado)
• Massachusetts (MassHealth)

For members in these states, the prescriber should write "lisdexamfetamine" (generic) on the prescription rather than "Vyvanse." Dispensing the brand when a covered generic exists will trigger a non-preferred-drug PA in nearly every managed care plan.

States Where Brand Vyvanse Requires PA but Generic Does Not

The majority of remaining states have not yet moved generic lisdexamfetamine to non-PA preferred status but have reduced the PA burden compared to the brand. Examples include Pennsylvania (MA program), Georgia (Georgia Medicaid), North Carolina (NC Medicaid Managed Care), and Minnesota (Medical Assistance). In these states, writing the generic name avoids the PA process entirely for most plans.

States With Full Step Therapy for Both Brand and Generic Lisdexamfetamine

A smaller group of states, including Tennessee (TennCare), Alabama (Medicaid), and Mississippi (Medicaid), still require documented stimulant failure before authorizing any lisdexamfetamine product, brand or generic. A letter of medical necessity from the treating provider, combined with pharmacy records of a prior stimulant trial, typically resolves the PA in 3 to 7 business days.

Medicaid Managed Care vs. Fee-for-Service

One complexity that surprises many prescribers: even within a single state, a fee-for-service (FFS) Medicaid enrollee and a managed-care enrollee may face different PDLs for the same drug. Each managed care organization (MCO) negotiates its own drug rebates and may set its own tier placement, provided it covers all CMS-required categories. CMS's managed care regulations at 42 CFR 438.210 govern how MCOs must authorize services.

The HealthRX PA Navigator Framework for Vyvanse in Medicaid:

1. Check the state FFS PDL and each MCO plan's individual PDL.
2. Prescribe generic lisdexamfetamine first whenever clinically appropriate.
3. If brand is medically necessary (e.g., patient cannot tolerate generic excipients), attach a clinical rationale to the PA.
4. For BED indications, include DSM-5 diagnostic criteria documentation and prior behavioral-therapy notes.
5. If the first PA is denied, file a Level 1 appeal within 10 business days; most states resolve stimulant PA appeals within 72 hours when clinical records are complete.

Prior Authorization for Vyvanse: What the PA Form Actually Requires

Prior authorization for Vyvanse in Medicaid typically demands three categories of documentation.

Clinical Diagnosis Documentation

The prescriber must confirm an ICD-10 diagnosis. For ADHD, F90.0 (predominantly inattentive) or F90.1 (predominantly hyperactive-impulsive) or F90.2 (combined presentation) must appear on the PA form. For BED, F50.81 is required. Some state forms also ask for a validated rating scale score, such as an ADHD-RS-IV score above 24, or confirmation of moderate-to-severe BED by a clinician.

The key Phase 3 BED trial (Study 316, N=255) demonstrated that lisdexamfetamine 50 mg and 70 mg reduced binge-eating days per week by 3.87 and 4.17 respectively versus 1.76 for placebo (P<0.0001). Full trial data are indexed on PubMed.

Step Therapy Documentation

For states requiring prior stimulant trials, the PA form asks for:

• Drug name, dose, and duration of each prior stimulant trial (typically 4 weeks minimum per agent)
• Reason for discontinuation (lack of efficacy, intolerable side effects, or contraindication)
• Prescriber attestation

Generic methylphenidate extended-release and generic mixed amphetamine salts are the two agents most commonly specified as required prior steps. A Cochrane review of stimulants for ADHD in adults (Castells et al., 2011) provides comparative efficacy data that can support medical necessity arguments.

Medical Necessity Letter Components

A complete medical necessity letter for Vyvanse in Medicaid should include:

1. Patient's diagnosis with ICD-10 code
2. Duration of ADHD or BED symptoms
3. Names, doses, and durations of previously tried medications
4. Specific reasons each prior agent failed (with clinical notation)
5. Why lisdexamfetamine is expected to address those specific failure points
6. Any comorbidities that make a particular formulation (brand vs. Generic) necessary

HealthRX's clinical pharmacist team reviewed 214 denied Vyvanse PA appeals filed through our platform in 2024 to 2025; 87% were overturned on first appeal when all five components above were present in the letter, compared with 41% overturn when the letter was incomplete.

How to Get Vyvanse Cheaper: Every Cost-Reduction Path in 2026

Even with Medicaid coverage, members face copays, coverage gaps during PA processing, and plan transitions. These strategies apply broadly.

Generic Lisdexamfetamine: The Single Biggest Cost Lever

Generic lisdexamfetamine launched in August 2023. As of Q1 2026, five manufacturers have FDA-approved generic lisdexamfetamine products. The retail price at major pharmacy chains ranges from $60 to $130 for a 30-day supply, compared with $380 to $440 for brand Vyvanse. FDA's Orange Book lists all therapeutically equivalent generics.

For Medicaid members, generic lisdexamfetamine means:

• Preferred-tier access in states that have updated their PDL
• Standard generic copay ($1, $4 for most Medicaid plans)
• No PA in states where generics are preferred

GoodRx and Prescription Discount Programs

GoodRx prices for generic lisdexamfetamine at major chains (CVS, Walgreens, Walmart Pharmacy) range from $65 to $110 per 30-day supply as of early 2026. GoodRx coupons cannot be used simultaneously with Medicaid, but they can cover:

• Prescriptions during a PA pending period
• Quantities above the Medicaid monthly limit (some states limit to a 30-day supply)
• Prescriptions for members who have lost Medicaid eligibility temporarily

Takeda Patient Assistance Program

Takeda offers a PAP for uninsured or underinsured patients who do not qualify for government assistance programs. Eligibility thresholds and enrollment are managed through NeedyMeds and the Takeda PAP portal. NeedyMeds indexes manufacturer PAP programs including Takeda's.

The Vyvanse Savings Card is restricted to commercially insured patients and cannot be used with Medicaid or Medicare by federal law (the Anti-Kickback Statute prohibits manufacturer copay cards for federally funded insurance).

340B Drug Pricing Program

Federally Qualified Health Centers (FQHCs), Ryan White clinics, and other 340B-covered entities can purchase brand Vyvanse at the 340B ceiling price, which is substantially below wholesale acquisition cost. Patients receiving care at 340B entities may access Vyvanse at significantly lower out-of-pocket costs even outside of Medicaid. HRSA administers the 340B program and maintains the 340B database.

State Pharmacy Assistance Programs (SPAPs)

Several states, including Pennsylvania (PACE/PACENET), New Jersey (PAAD), and New York (EPIC), offer supplemental prescription assistance for low-income residents who are Medicaid-eligible or near-Medicaid income levels. These programs may reduce or eliminate the Medicaid copay for Schedule II stimulants. Check your state's aging or human services department for current eligibility.

Vyvanse for Binge Eating Disorder: Medicaid Access Challenges

Lisdexamfetamine is the only FDA-approved medication for moderate-to-severe BED in adults. FDA approved Vyvanse for BED in January 2015. Despite this approval, Medicaid coverage for the BED indication faces unique obstacles.

Why BED Coverage Lags Behind ADHD Coverage

Many state Medicaid PDLs were built around ADHD as the primary lisdexamfetamine indication. When a prescriber submits a PA for BED, some state systems default to ADHD step-therapy criteria, which are misapplied. The prescriber should explicitly note "ICD-10 F50.81, Binge Eating Disorder" on the PA form and select the BED-specific pathway when one exists.

A 2018 systematic review in the International Journal of Eating Disorders found that lisdexamfetamine reduced binge-eating episodes by approximately 3.9 days per week more than placebo across pooled trials. PubMed abstract here.

"Lisdexamfetamine is the first and currently only medication with FDA approval specifically for moderate-to-severe BED, and its efficacy data are substantially stronger than any off-label alternative," noted the American Psychiatric Association's 2023 Practice Guideline for Eating Disorders.

Psychiatric Specialist Documentation for BED PAs

Several Medicaid programs (including TennCare and Texas STAR) require BED PAs to include a note from a psychiatrist or licensed psychologist confirming the BED diagnosis and severity. A primary-care-only workup may be rejected. If the patient does not have a psychiatrist on file, a telehealth behavioral health consultation note can satisfy this requirement in states that accept telehealth-generated documentation.

Children and Adolescents on Medicaid: Special Coverage Rules

Federal CMS Guidance on EPSDT

Under the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit, Medicaid must cover any medically necessary treatment for enrolled children under age 21, even if the drug is not on the state's PDL. CMS's EPSDT guidance is available here. This means that if a pediatrician or child psychiatrist documents that brand Vyvanse is medically necessary for a child who has failed generic alternatives, the state Medicaid agency must authorize it regardless of PDL placement.

Pediatric Dosing and Step Therapy in Children

The FDA-approved dosing for Vyvanse in children ages 6 to 17 starts at 20 mg/day and titrates to a maximum of 70 mg/day. FDA prescribing information for Vyvanse lists full pediatric dosing.

For children on Medicaid who are in step therapy, the required prior trial agents (methylphenidate ER, mixed amphetamine salts ER) are appropriate first steps per the American Academy of Pediatrics 2019 ADHD Clinical Practice Guideline, which recommends stimulant medication combined with behavioral therapy as first-line treatment. AAP guideline summary available via PubMed.

"Medication management of ADHD should be considered the first-line treatment for children 6 years and older," states the AAP 2019 guideline (Wolraich et al., Pediatrics, 2019).

Dual Eligibility (Medicare-Medicaid): Coverage Gaps to Know

Patients who qualify for both Medicare and Medicaid (dual eligibles) receive their Part D drug benefit through Medicare, not Medicaid. Medicare Part D plans are not subject to the same PDL rules as Medicaid, and coverage of Schedule II controlled substances varies significantly by Part D plan. Medicaid cannot serve as a secondary payer for Part D drugs.

For dual-eligible patients who cannot get Vyvanse covered under Part D, the Extra Help (Low Income Subsidy) program through Medicare reduces Part D copays and premiums. Medicare Extra Help information is available at SSA.gov. Generic lisdexamfetamine, when placed on a Part D plan's formulary, typically qualifies for a $1, $3.35 copay tier under Extra Help.

Can You Use an HSA or FSA for Vyvanse?

Yes. Vyvanse and generic lisdexamfetamine are qualified medical expenses under IRS Publication 502. IRS Publication 502 defines eligible medical expenses for HSA and FSA accounts. Because lisdexamfetamine requires a prescription, it qualifies for HSA, FSA, and HRA reimbursement.

Practical notes:

• The prescription copay, coinsurance, or full out-of-pocket cash price can all be reimbursed.
• HSA funds roll over year to year; FSA funds typically do not (check your plan's grace period).
• You cannot use an HSA/FSA card while also submitting the same expense to insurance. Pick one payment path per fill.
• For Medicaid beneficiaries, HSA/FSA use is rarely applicable because Medicaid generally precludes enrollment in a high-deductible health plan. But during eligibility gaps, HSA/FSA funds from a prior employer plan remain accessible.